Effect of Hypoxia-inducible Factor-1 Alpha Expression on Survival in Patients with Metastatic Cervical Squamous Cell Carcinoma Treated with First-line Chemotherapy and Bevacizumab

Overview

Journal Biomol Biomed

Specialties Biochemistry
General Medicine

Date 2024 Mar 6

PMID 38447002

Authors

Hasan Cagri Yildirim

Hicran Anik

Deniz Ates Ozdemir

Rashad Ismayilov

Arif Akyildiz

Kerim Cayiroz

Fahri Ceyhan

Oguzalp Kavruk

Deniz Can Guven

Ozturk Ates

Alp Usubutun

Zafer Arik

Affiliations

Soon will be listed here.

Abstract

This study addresses the gap in understanding the prognostic relevance of hypoxia-inducible factor-1 alpha (HIF-1 alpha) expression in metastatic cervical squamous cell carcinoma (SCC) patients undergoing anti-vascular endothelial growth factor (VEGF)-based therapy. A retrospective multicenter study (n = 34) explored HIF-1 alpha expression via immunohistochemistry in patients treated with platinum chemotherapy and bevacizumab. Median progression-free survival (PFS) was significantly lower in the HIF-1 alpha low score group compared to the high score group (4.9 vs 12.9 months, P = 0.014). Similarly, the median overall survival (OS) was significantly reduced in the HIF-1 alpha low score group (8.3 vs 20.4 months, P = 0.006). This study, the first of its kind, highlights the prognostic significance of HIF-1 alpha expression in metastatic cervical SCC patients treated with bevacizumab-based therapy.

References

Fu Z, Chen D, Cheng H, Wang F . Hypoxia-inducible factor-1α protects cervical carcinoma cells from apoptosis induced by radiation via modulation of vascular endothelial growth factor and p53 under hypoxia. Med Sci Monit. 2015; 21:318-25. PMC: 4316866. DOI: 10.12659/MSM.893265. View

Semenza G . HIF-1 and human disease: one highly involved factor. Genes Dev. 2000; 14(16):1983-91. View

Tewari K, Sill M, Penson R, Huang H, Ramondetta L, Landrum L . Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017; 390(10103):1654-1663. PMC: 5714293. DOI: 10.1016/S0140-6736(17)31607-0. View

Penson R, Huang H, Wenzel L, Monk B, Stockman S, Long 3rd H . Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncol. 2015; 16(3):301-11. PMC: 4479218. DOI: 10.1016/S1470-2045(15)70004-5. View

Tommasino M . The human papillomavirus family and its role in carcinogenesis. Semin Cancer Biol. 2013; 26:13-21. DOI: 10.1016/j.semcancer.2013.11.002. View

Colombo N, Dubot C, Lorusso D, Caceres M, Hasegawa K, Shapira-Frommer R . Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N Engl J Med. 2021; 385(20):1856-1867. DOI: 10.1056/NEJMoa2112435. View

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

Tewari K, Sill M, Long 3rd H, Penson R, Huang H, Ramondetta L . Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014; 370(8):734-43. PMC: 4010094. DOI: 10.1056/NEJMoa1309748. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View

10.

Menard S, Fortis S, Castiglioni F, Agresti R, Balsari A . HER2 as a prognostic factor in breast cancer. Oncology. 2001; 61 Suppl 2:67-72. DOI: 10.1159/000055404. View

11.

Kim B, Cho H, Chung J, Conway C, Ylaya K, Kim J . Prognostic assessment of hypoxia and metabolic markers in cervical cancer using automated digital image analysis of immunohistochemistry. J Transl Med. 2013; 11:185. PMC: 3750663. DOI: 10.1186/1479-5876-11-185. View

12.

Chen L, Shi Y, Yuan J, Han Y, Qin R, Wu Q . HIF-1 alpha overexpression correlates with poor overall survival and disease-free survival in gastric cancer patients post-gastrectomy. PLoS One. 2014; 9(3):e90678. PMC: 3948685. DOI: 10.1371/journal.pone.0090678. View

13.

Kraus J, Dabbs D, Beriwal S, Bhargava R . Semi-quantitative immunohistochemical assay versus oncotype DX(®) qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study. Mod Pathol. 2012; 25(6):869-76. DOI: 10.1038/modpathol.2011.219. View

14.

Gasparini G, Longo R, Toi M, Ferrara N . Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol. 2005; 2(11):562-77. DOI: 10.1038/ncponc0342. View

15.

Martinez-Ramirez I, Carrillo-Garcia A, Contreras-Paredes A, Ortiz-Sanchez E, Cruz-Gregorio A, Lizano M . Regulation of Cellular Metabolism by High-Risk Human Papillomaviruses. Int J Mol Sci. 2018; 19(7). PMC: 6073392. DOI: 10.3390/ijms19071839. View

16.

Ellis M, Coop A, Singh B, Mauriac L, Janicke F, Miller W . Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001; 19(18):3808-16. DOI: 10.1200/JCO.2001.19.18.3808. View

17.

Zheng S, Chen X, Yin X, Zhang B . Prognostic significance of HIF-1α expression in hepatocellular carcinoma: a meta-analysis. PLoS One. 2013; 8(6):e65753. PMC: 3683060. DOI: 10.1371/journal.pone.0065753. View

18.

Guo Y, Meng X, Ma J, Zheng Y, Wang Q, Wang Y . Human papillomavirus 16 E6 contributes HIF-1α induced Warburg effect by attenuating the VHL-HIF-1α interaction. Int J Mol Sci. 2014; 15(5):7974-86. PMC: 4057713. DOI: 10.3390/ijms15057974. View

19.

Wang X, Huang X, Zhang Y . Involvement of Human Papillomaviruses in Cervical Cancer. Front Microbiol. 2018; 9:2896. PMC: 6279876. DOI: 10.3389/fmicb.2018.02896. View

20.

Carmeliet P . VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005; 69 Suppl 3:4-10. DOI: 10.1159/000088478. View